| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 181 | ANTIPROTOZOAL HISTONE ACETYL TRANSFERASE INHIBITORS | PCT/US2000/027337 | 2000-10-04 | WO01027314A1 | 2001-04-19 | |
| Histone acetyl transferase inhibition provides a target for identifying potential antiprotozoal compounds. Histone acetyl transferase inhibitors are useful as therapeutic agents against protozoal infections. A method of identifying histone acetyl transferase inhibitors compares i) the acetylation level from a combination of a test compound with a known histone deacetylase inhibitor to ii) a basal acetylation level. | ||||||
| 182 | USE OF RETINOIC ACID ACTIVITY INHIBITORS TO SLOW DOWN HAIR LOSS | PCT/FR1999/000687 | 1999-03-24 | WO99049838A1 | 1999-10-07 | |
| The invention concerns the use in or for preparing a cosmetic or pharmaceutical, preferably dermatological, composition, of at least a retinoic activity inhibitor, said composition being designed to slow down or preventing the growth of hairs and/or hair. Said composition is also designed to slow down loss of hairs and/or hair. | ||||||
| 183 | USE OF RIMINOPHENAZINES AS ANTIMICROBIAL AND ANTIMALARIAL AGENTS | PCT/GB1997001395 | 1997-05-21 | WO1997045120A1 | 1997-12-04 | UNIVERSITY OF PRETORIA; KINTON, Colin, David |
| A substance or composition for use in a method of treatment of a gram-positive bacterial infection of the human or animal body by the administration of said substance or composition to the human or animal body, said substance or composition comprising a compound of formula (II): in which R<1> and R<4> are the same and each is a halogen atom, a haloalkyl radical or an isopropyl radical, n is 1, 2 or 3 and represents the number of R<1> substituents and of R<4> substituents, R<2> is hydrogen, halogen or haloalkyl, and TMP is a tetramethyl piperidyl radical, with the provisos that (a) when n is 2, R<1>n and R<4>n are not 3,4-dichloro- and (b) when n is 1, R<1> and R<4> are not 4-trifluoromethyl-. The bacterial infection may be one or more of the species selected from Mycobacterium aurum, Mycobacterium tuberculosis, Mycobacterium chelonae, Mycobacterium abscessus, Mycobacterium fortuitus, Streptococcuspneumoniae, Enterococcus sp. and Staphylococcus aureus. The compounds may be administered in effective amounts. Also provided as novel pharmaceutically active compounds are N,5-bis(3-chloro-4-fluorophenyl)-3,5-dihydro-3-[(2',2',6',6'-tetramethyl-4-piperidyl)-imino]-2-phenazinamine and N,5-bis(2-chlorophenyl)-3,5-dihydro-3-[(2',2',6',6'-tetramethyl-4-piperidyl)-imino]-2-phenazinamine. | ||||||
| 184 | METHODS FOR IDENTIFYING INHIBITORS OF FUNGAL PATHOGENICITY | PCT/US1995002311 | 1995-02-24 | WO1995023235A1 | 1995-08-31 | MYCO PHARMACEUTICALS INC.; BULAWA, Christine, E. |
| Methods of detecting inhibitors of fungal pathogenicity are disclosed. These methods are based on the discovery that pathogenicity is diminished when chitin synthase III is inhibited. The inhibitors of fungal pathogenicity are detected with mutant strains of S. cerevisiae or other mutant fungal strains, whose mutation causes diminished growth of the fungus when combined with the inhibition of chitin synthase III. | ||||||
| 185 | SENESCENT CELL DERIVED INHIBITORS OF DNA SYNTHESIS | PCT/US1992010904 | 1992-12-15 | WO1993012251A1 | 1993-06-24 | BAYLOR COLLEGE OF MEDICINE; SMITH, James, R. |
| An expression vector cDNA library derived from senescent cells has been used to isolate cDNA clones that encode inhibitors of DNA synthesis. Such inhibitors play a role in cellular senescence and aging. Antisense nucleic acids reduce the inhibition of DNA synthesis. | ||||||
| 186 | Antiarrhythmic drug and atrial fibrillation inhibitor | JP2012018977 | 2012-01-31 | JP2012236814A | 2012-12-06 | SUGIYAMA ATSUSHI |
| PROBLEM TO BE SOLVED: To provide an antiarrhythmic drug and an atrial fibrillation inhibitor having an excellent inhibitory action relative to arrhythmia including atrial fibrillation, less side effects and high stability, a sustained atrial fibrillation model suitably used for screening of the atrial fibrillation and a method for producing the same, and a method for screening the atrial fibrillation inhibitor.SOLUTION: An atrial fibrillation inhibitor comprises a compound represented by any of formula (I) to (VI) or a pharmacologically acceptable salt thereof. In formula (III), Gluc represents glucuronic acid. | ||||||
| 187 | Formation inhibitor for fungi melanin and composition containing the same | JP11780998 | 1998-04-13 | JPH11293300A | 1999-10-26 | TAKEUCHI KEIJI; TAKAHASHI KENJI; NAKAMURA AKIRA; HIRABAYASHI NORITOSHI |
| PROBLEM TO BE SOLVED: To obtain a formation inhibitor which is effective in inhibiting the formation of and in removing melanin due to black aspergillus, or the like, appearing in bathrooms, or the like, liable to be wet by using, as the effective component, a compd. selected from among triterpenes, retinolic acid derivs., sphingoid compds., and sulindac. SOLUTION: Triterpenes are classified into the α-amyrin group, the β-amyrin group, the lupeol group, the nosterin group, and the squalene group, among which the lupeol group is suitable, more specifically, betulic acid is esp. suitable. As the retinolic acid deriv., 4-hydroxyphenylretinamide is esp. suitable. As the sphingoid compd., for example, 16-20C sphingolipids are listed; more specifically, ceramides, sphingoglycolipids, sphingophospholipids, or the like, are listed as sphingolipids. At least one of these compds. is compounded pref. in am amt. of 0.01-50 wt.% of the compsn. COPYRIGHT: (C)1999,JPO | ||||||
| 188 | Screening of fungicide utilizing dhod inhibitor | JP1130993 | 1993-01-27 | JPH06113889A | 1994-04-26 | JIYOOJI II DEIBISU; GEIRII DEII GUSUTAFUSON; MASHIYUU JIEI HENRII; EIMII JIEI SUMISU; KURIIBU UORUDORON |
| PURPOSE: To provide a method for identifying a latent fungicide. CONSTITUTION: Dihydroorotate dehydrogenase(DHOD) inhibition assays are utilized in the method for identifying a new plant fungicide. COPYRIGHT: (C)1994,JPO | ||||||
| 189 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI RESISTANT TO QO INHIBITORS | PCT/EP2012/074586 | 2012-12-06 | WO2013092224A1 | 2013-06-27 | RHEINHEIMER, Joachim; TERTERYAN, Violeta; REDLICH, Stefan; KREMZOW, Doris; ROSENBAUM, Claudia; ROHRER, Sebastian Georgios; GRAMMENOS, Wassilios; PILGER, Christian; RÖHL, Franz; GEWEHR, Markus; STAMMLER, Gerd; MONTAG, Jurith; SAUTER, Hubert |
The present invention relates to the use of strobilurine type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, to plant health 10 applications, and to seeds coated with at least one such compound. |
||||||
| 190 | 赤かび病菌かび毒産生抑制剤 | JP2015160764 | 2015-08-18 | JP2017039649A | 2017-02-23 | 木村 眞; 前田 一行; 中嶋 佑一; 長田 裕之; 本山 高幸; 斉藤 臣雄; 近藤 恭光 |
| 【課題】赤かび病菌のかび毒抑制剤及び赤かび病菌のかび毒抑制方法の提供。 【解決手段】式(1)で表される化合物及び薬学的に許容される塩の少なくとも1つ以上を有効成分とする赤かび病菌のかび毒抑制剤、及び該抑制剤による赤かび病菌のかび毒産生を抑制する方法。 (R1は−COCH3、−OH、−COCH2OH又は−C≡C;R2は−H又は−OH;R3は−H又は−OH;R4はアミノ酸又はアミノ酸類縁体) 【選択図】図1 |
||||||
| 191 | Angiotensin i converting enzyme inhibitor and antihypertensive functional food | JP2001217894 | 2001-07-18 | JP2003024012A | 2003-01-28 | MARUYAMA SUSUMU; AIDA JUON |
| PROBLEM TO BE SOLVED: To obtain an angiotensin I converting enzyme inhibitor having as the active ingredient a peptide derived from a natural product and excellent in absorbency, to provide an antihypertensive functional food having as the active ingredient the peptide, and to provide a nutrient preparation having as the active ingredient the peptide. SOLUTION: The angiotensin I converting enzyme inhibitor has as the active ingredient a dipeptide such as Ala-Pro existing in a fermentation product obtained by fermenting a fish fresh hydrolyzate or in a fish and shellfish seasoning. The antihypertensive functional food having as the active ingredient the dipeptide and also the nutrient preparation having as the active ingredient the dipeptide are provided. | ||||||
| 192 | Hyaluronidase activity inhibitor, antibacterial agent against helicobacter pylori, and bamboo extract composition | JP2006346375 | 2006-12-22 | JP2008156270A | 2008-07-10 | MIYAZAKI AIKO; YOSHINO AKIRA; TAKESHITA KEI |
| <P>PROBLEM TO BE SOLVED: To provide a hyaluronidase activity inhibitor containing as a component a safe and easily ingestable bamboo extract composition using the skin of Phyllostachys pubescens of a natural product as a raw material, to provide an antibacterial agent against Helicobacter pylori, and to provide a safe and easily ingestable bamboo extract composition using the skin of the Phyllostachys pubescens of the natural product. <P>SOLUTION: The hyaluronidase activity inhibitor contains the bamboo extract composition obtained by adding an organic solvent or the organic solvent and water to a treated material obtained by treating the bamboo skin by a hydrolysis method to carry out the extraction as an active ingredient. The inhibitor can inhibit the development of allergy affected by the hyaluronidase activity and gastritis or the like caused by the Helicobacter pylori, because the bamboo extract composition has the hyaluronidase activity-inhibiting activity and the germicidal activity effective to the Helicobacter pylori. <P>COPYRIGHT: (C)2008,JPO&INPIT | ||||||
| 193 | ＱＯ 저해제에 대해 내성을 갖는 식물병원성 진균 방제를 위한 스트로빌루린형 화합물의 용도 | KR1020147020070 | 2012-12-06 | KR1020140107510A | 2014-09-04 | 라인하이머요아힘; 테르테리안피올레타; 레들리히슈테판; 크렘초브도리스; 로젠바움클라우디아; 롤러세바슈티안게오르기오스; 그람메노스바실리오스; 필거크리슈티안; 뢸프란츠; 게베어마르쿠스; 슈탐러게르트; 몬타크유리트; 자우터후베르트 |
| 본 발명은 Qo 저해제에 대한 내성을 부여하는 미토콘드리아 시토크롬 b 유전자에서의 돌연변이를 포함하는 식물병원성 진균의 방제를 위한 식 I 의 스트로빌루린형 화합물 및 이의 N-산화물 및 염의 용도, 및 이러한 진균 방제를 위한 방법에 관한 것이다. 본 발명은 또한 신규한 화합물, 이들 화합물 제조 공정, 하나 이상의 이러한 화합물을 포함하는 조성물, 식물 검역 적용, 및 하나 이상의 이러한 화합물로 코팅된 종자에 관한 것이다. | ||||||
| 194 | INHIBITORS OF RTT109 AS ANTI-FUNGAL AGENTS | PCT/US2012/043785 | 2012-06-22 | WO2012178036A2 | 2012-12-27 | ZHANG, Zhiguo; LIMPER, Andrew, H.; HAN, Junhong; ZHOU, Hui; KOTTOM, Theodore, J.; HOOK, Derek; BERMAN, Judith; WALTERS, Michael, Anthony |
This document relates to materials and methods for identifying chemical inhibitors of fungal targets useful for treating organisms infected with opportunistic fungal pathogens. For example, this document provides the materials and methods for identifying and optimizing chemical inhibitors of Rtt109, a fungal histone acetyltransferase. This document also provides the materials and methods for using high throughput screening technologies to identify candidate chemical inhibitors of Rtt109 as well as the materials and methods for evaluating candidate chemical inhibitors of Rtt109 in secondary screens for their binding efficacy, molecular specificity, and cellular toxicity. |
||||||
| 195 | CARBONIC ANHYDRASE INHIBITORS TO ERADICATE HELICOBACTER PYLORI | PCT/US2004/010089 | 2004-04-02 | WO2004091611A1 | 2004-10-28 | SCOTT, David, R.; MARCUS, Elizabeth, A.; SACHS, George |
Inhibitors of the alpha carbonic anhydrase inhibitors are administered to treat H pylori infection in the mammalian, including human, stomach. The inhibitors are administered to mammals, including humans, in an amount that results in 4 X 10-4 to 4 X 10-9 Molar concentration of the drug in the stomach because this concentration range is lethal to the H. pylori bacteria. |
||||||
| 196 | SCREEN FOR INHIBITORS OF FUNGAL IPC SYNTHASE | PCT/US1998/006897 | 1998-04-06 | WO98045426A1 | 1998-10-15 | |
| This invention provides novel fungal strains altered in IPC synthase production, and a method for screening for inhibitors of fungal IPC synthase using whole cells. | ||||||
| 197 | TANNIN STAINING AND FUNGUS GROWTH INHIBITOR PIGMENT | PCT/US1995016351 | 1995-12-18 | WO1996020794A1 | 1996-07-11 | WAYNE PIGMENT CORPORATION; SINKO, John |
| A process of inhibiting of the staining of a film forming finish applied to a tannin containing wood substrate includes the step of applying to the wood substrate prior to or concurrently with the film forming finish, a protective coating containing an effective amount of zinc cyanamide to inhibit the migration of tannins from the substrate into the finish. | ||||||
| 198 | ORAL DOSAGE FORMS INCLUDING AN ANTIPLATELET AGENT AND AN ACID INHIBITOR | PCT/US2007065967 | 2007-04-04 | WO2007115305A2 | 2007-10-11 | GOLDSMITH MARK A; VADAS ELIZABETH |
| The present disclosure provides oral dosage forms comprising an antiplatelet agent and an acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an acid inhibitor. | ||||||
| 199 | VIRAL AND FUNGAL INHIBITORS | EP09818273.6 | 2009-09-23 | EP2344481B9 | 2014-12-31 | PADMANABHAN, Radhakrishnan; GROUTAS, William C.; KORBA, Brent E. |
| 200 | ＮＦκＢ-억제제 및 비-레티노이드 콜라겐 촉진제를 포함하는 조성물 | KR1020100095966 | 2010-10-01 | KR1020110036682A | 2011-04-08 | 카우르시마나; 오도스티에리; 서덜마이클; 터커-사마라스사만다 |
| PURPOSE: A composition containing NF-kappaB inhibitor and non-retinoid collagen promoting agent is provided to promote collagen activity and to treat skin aging. CONSTITUTION: A composition contains NF-kappa B inhibitor and non-retinoid collagen promoting agent, The NF-kappaB inhibitor is substituted resorcinol, (E)-3-(4-methylphenylsulfonyl)-2-propennitrile, tetrahydrocurcuminoid, or mixture thereof. The substituted resorcinol contains a substituent without a phenyl functional group and ketone functional group. The non-retinoid collagen promoting agent is Tanacetum parthenium or Centella asiatica extract. | ||||||
QQ群二维码
意见反馈
意见反馈